Review Article

The Role of the Endothelium in HPS Pathogenesis and Potential Therapeutic Approaches

Irina Gavrilovskaya, Elena Gorbunova, Valery Matthys, Nadine Dalrymple, and Erich Mackow

Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY 11794-5222, USA

Correspondence should be addressed to Erich Mackow, erich.mackow@stonybrook.edu

Received 27 January 2012; Revised 16 May 2012; Accepted 18 May 2012

Copyright © 2012 Irina Gavrilovskaya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

American hantaviruses cause a highly lethal acute pulmonary edema termed hantavirus pulmonary syndrome (HPS). Hantaviruses nonlytically infect endothelial cells and cause dramatic changes in barrier functions of the endothelium without disrupting the endothelium. Instead hantaviruses cause changes in the function of infected endothelial cells that normally regulate fluid barrier functions of capillaries. The endothelium of arteries, veins, and lymphatic vessels is unique and central to the function of vast pulmonary capillary beds, which regulate pulmonary fluid accumulation. The endothelium maintains vascular barrier functions through a complex series of redundant receptors and signaling pathways that serve to both permit fluid and immune cell efflux into tissues and restrict tissue edema. Infection of the endothelium provides several mechanisms for hantaviruses to alter capillary permeability but also defines potential therapeutic targets for regulating acute pulmonary edema and HPS disease. Here we discuss interactions of HPS causing hantaviruses with the endothelium, potential endothelial cell-directed permeability mechanisms, and therapeutic targeting of the endothelium as a means of reducing the severity of HPS disease.

1. Introduction

Hantaviruses predominantly infect microvascular endothelial cells (ECs), which line vessels and nonlytically cause two vascular diseases: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) [1–14]. The mechanisms by which hantaviruses cause capillary leak syndromes and disrupt fluid barrier integrity of the endothelium are beginning to be disclosed and appear to involve dysregulating EC functions that normally limit fluid leakage from the vasculature [6, 15–21].

Capillaries, veins, and lymphatic vessels are lined by a single layer of ECs which collectively form one of the largest tissues of the body [22, 23]. The endothelium forms a primary fluid barrier within vessels as well as serves more than just a conduit for blood to reach and return from organs [22, 24]. The endothelium selectively restricts blood and plasma from entering tissues, regulates immune cell infiltration, and responds to damage by limiting leakage, repairing vessels, and directing angiogenesis [22]. Consequently, capillary barrier integrity is redundantly regulated by an array of EC-specific effectors that coordinate balance vascular fluid containment with tissue-specific needs and respond to a host of systemic and locally generated factors that alter inter-endothelial cell adherence junctions [22, 25–37]. ECs respond to activated platelets and immune cells, clotting cascades, chemokines and cytokines, growth factors, nitric oxide, and hypoxic conditions [22, 27, 29, 38–41]. However, ECs also secrete cytokines, complement and growth factors that positively or negatively impact the adherence and activation of platelets and immune cells, regulate responses to hypoxia, and diminish or enhance extravasation of fluid into tissues [22, 24, 26, 27, 30, 40–45]. Each of these EC responses is controlled by a diverse mesh of intertwined sensors and signals aimed at returning the endothelium to a resting state, countering permeabilizing effectors, repairing vessel damage, and restoring fluid and oxygenation levels within tissues [22, 25, 39, 41, 46–51].

The endothelium of capillaries, veins, and lymphatic vessels are unique and central to discrete functions of vast
Infection of ECs is nonlytic and the permeability of infected
250 kDa RNA-dependent RNA polymerase [14, 67, 70]. The
2. Hantavirus Infection and HPS Disease
advances in virology
approaches have thus far proven elusive.
[69]; however, gene reassortment has not permitted the
exchanged between closely related HPS causing hantaviruses
bunyaviridae
family [14, 65]. Hantaviruses are the only members of the
bunyaviridae
to their hosts [13, 14, 66–68]. Single genes have been
protein sequences, which are likely the result of coadaptation
hosts, and hantaviruses contain highly divergent RNA and
permeability, a decrease in lymphatic vessel clearance of
tissue fluids is also a cause of edema and regulated by
unique lymphatic endothelial cells (LECs) [42, 53, 54, 61].
Vascular permeability induced by nonlytic viruses is likely
to be multifactorial in nature, resulting from virally altered
EC responses, immune cell and platelet functions, hypoxia,
or a collaboration of dysregulated interactions that impact
normal fluid barrier function [15–18, 20, 27, 62–64]. Failure
of the endothelium to regulate fluid accumulation in tissues
has pathologic consequences and during HPS results in
localized vascular permeability and acute pulmonary edema
that contribute to cardiopulmonary insufficiency [4–6, 9]. Here
we focus on the mechanisms by which HPS causing
hantavirus infection of ECs induces vascular permeability
and acute edema and discuss potential therapeutic
mechanisms that may stabilize the endothelium.

2. Hantavirus Infection and HPS Disease

Hantaviruses are enveloped, tripartite, negative-sense RNA
viruses and form their own genus within the Bunyaviridae
family [14, 65]. Hantaviruses are the only members of the
Bunyaviridae that are transmitted to humans by mammalian
hosts, and hantaviruses contain highly divergent RNA and
protein sequences, which are likely the result of coadaptation
with their hosts [13, 14, 66–68]. Single genes have been
exchanged between closely related HPS causing hantaviruses
[69]; however, gene reassortment has not permitted the
discovery of pathogenic determinants and reverse genetics
approaches have thus far proven elusive.

The hantavirus genome consists of three segments
denoted S, M, and L based on the length of their RNA
segments, respectively [14]. The L segment encodes the
250 kDa RNA-dependent RNA polymerase [14, 67, 70]. The
S segment encodes a 48 kDa nucleocapsid (N) protein which
is the most abundant hantavirus antigen present in infected
cells [14, 70, 71]. The M segment encodes two viral surface
glycoproteins Gn (64 kDa) and Gc (54 kDa) that are cotrans-
lationally cleaved and targeted to the ER/cis-Golgi [14, 72].
Hantaviruses bud internally into the lumen of the cis-Golgi
and exit cells via a secretory mechanism consistent with aber-
rant vesicular trafficking [14]. Hantaviruses are both released
from ECs and remain cell associated through interactions
with cell surface receptors [15, 62, 73]. GnGc heterodimers
on the virion surface are presumed to bind cellular receptors
and mediate viral entry into cells [14, 15, 16, 20, 72–79].

Hantaviruses are one of only a few viruses that primarily
infect the EC lining of the vasculature [8, 9, 12, 80, 81].
Hantaviruses replicate to low titers, with initial viral progeny
emerging from infected ECs 18–24 hours postinfection (hpi),
and ∼5 × 10^6 maximal titers days after infection [14].
Infection of ECs is nonlytic and the permeability of infected
EC monolayers is not increased by infection alone [14, 16,
82]. Prototypic HFRS (Hantaan virus-HTNV), HPS (SNV,
ANDV, NY-IV) [3, 5, 10, 83, 84], and nonpathogenic (Tula-
virus-TULV and Prospect Hill virus-PHV) [85–87] hantavi-
viruses all infect human ECs regardless of their ability to
cause disease, suggesting that EC entry alone is not a cause of
pathogenesis [12, 16, 81]. At least two requirements for han-
taviruses to be pathogenic have been determined thus far, the
ability of hantaviruses to regulate early interferon responses
and the use of specific integrins by pathogenic (ANDV, SNV,
NY-IV, PUUV, SEOV, HTNV) but not nonpathogenic (PHV,
TULV) hantaviruses [20, 76, 77, 79, 88–91].

2.1. Endothelial Cell Attachment and Entry. The cellular
entry of pathogenic hantaviruses is dependent on the presence
of αβ3 integrins on human ECs, while nonpathogenic
hantaviruses PHV and TULV use αβ3 integrins [76, 77]. Cells
expressing recombinant αβ3 or αββ3 facilitate infection
by SNV, NY-IV, ANDV, and HTNV, and infection is
blocked by antibodies to β3 integrins and by the β3 integrin
ligand vitronectin [62, 76]. NY-1V and ANDV bind β3
integrins in an RGD-independent fashion via interactions
with plexin-semaphorin-integrin (PSI) domains present at
the apex of bent, inactive, αβ3 integrin conformers [20, 79,
92–95]. Hantavirus binding to β3 maintains the integrin in a
resting state and inhibits EC migration on the high-affinity
αβ3 integrin ligand vitronectin [20, 62]. Infected ECs
contain cell associated hantaviruses on their surface at late
times post infection [15, 62, 73]. Cell associated pathogenic
hantaviruses further direct the binding of quiescent platelets
to the EC surface [15]. This interaction may mask hantavirus
infected cells or contribute to thrombocytopenia, which is a
prominent feature of hantavirus patients. Curiously,
αβ3 integrins present on ECs normally regulate vascular
permeability, and inhibiting β3 integrin functions alone
causes vascular permeability disorders [41, 95–100]. Links
between hantavirus dysregulation of αβ3 functions and their
role in EC permeability are discussed in detail below.

2.2. HPS Disease. At least 17 hantaviruses cause HPS,
also termed hantavirus cardiopulmonary syndrome (HCPS),
with prototype HPS viruses, Sin Nombre (SNV) in North
America and Andes (ANDV) in South America [4–9, 101–
104]. ANDV, SNV, and many closely related hantaviruses
cause HPS resulting in acute pulmonary edema, cardiopul-
monary insufficiency, and ∼35–40% mortality rates [4–9, 13,
101–103, 105–109]. One to two weeks after infection, there is
a rapid onset of pulmonary edema and hypoxia that occurs
6–12 hours after cough and rapidly progresses in severity
[4–6]. Bilateral pulmonary infiltrates may be interstitial or
alveolar with liters of pleural effusions observed during SNV
infection [4–6, 8, 9].

Hantavirus antigen is found predominately in vast
pulmonary capillary EC beds but is present in ECs within
lymph nodes and throughout the body [8, 9, 80]. However,
cytopathic effects are not evident following hantavirus
infection of ECs in vitro or in vivo [9, 16, 82]. Histologically,
the heart, kidneys, brain, and adrenals are grossly normal

renal and pulmonary capillary beds [42, 52–54]. Nonlytic
viral infection of ECs may disengage one or more fluid
barrier regulatory mechanisms, thereby increasing vascular
leakage or fluid clearance and as a consequence result in
tissue edema [55–60]. Although the edematous accumula-
tion of interstitial fluids can result from increased endothelial
permeability, a decrease in lymphatic vessel clearance of
tissue fluids is also a cause of edema and regulated by
unique lymphatic endothelial cells (LECs) [42, 53, 54, 61].
Vascular permeability induced by nonlytic viruses is likely
to be multifactorial in nature, resulting from virally altered
EC responses, immune cell and platelet functions, hypoxia,
or a collaboration of dysregulated interactions that impact
normal fluid barrier function [15–18, 20, 27, 62–64]. Failure
of the endothelium to regulate fluid accumulation in tissues
has pathologic consequences and during HPS results in
localized vascular permeability and acute pulmonary edema
that contribute to cardiopulmonary insufficiency [4–6, 9]. Here
we focus on the mechanisms by which HPS causing
hantavirus infection of ECs induces vascular permeability
and acute edema and discuss potential therapeutic
mechanisms that may stabilize the endothelium.
with pulmonary alveoli filled with acellular proteinaceous fluid, yet the alveolar epithelium remains intact [4–6, 8, 9]. The most striking HPS findings are edematous lungs with up to 8 liters of pleural edema [5, 6, 8, 9]. Pulmonary edema fluid contains few leukocytes, is largely serous in nature, and is consistent with the nearly complete loss of an alveolar capillary fluid barrier [4–6, 9]. The lack of disrupted endothelium during HPS is similar to edematous pulmonary responses observed in patients with high altitude-induced pulmonary edema [40, 60, 110–112]. The rapid onset of edematous symptoms during hantavirus infection [6] further suggests the importance of targeting vessel stability in regulating highly lethal hantavirus disease.

3. Vascular and Lymphatic Endothelium: Control of Vascular Fluid Barrier Functions

The endothelium lines a series of discrete vessel types that conduct fluids to and from tissues, directs the transfer of nutrients, wastes and oxygen and coordinates tissue responses to changing conditions and pathogens [22, 24, 27, 54, 59, 113–119]. Vascular ECs serve mainly as a conduit in the lining of high pressure arteries but take on a variety of fluid and cellular barrier functions in low pressure veins and capillaries that innervate organs and tissues [54]. Lymphatic vessels have a primary role in draining fluid, proteins, and immune cells from tissues and returning these components to the venous circulation [42, 52–54, 114]. Depending on their location, lymphatic vessels serve discrete fluid barrier and regulatory functions, keeping pulmonary alveolar spaces dry and clearing fluid influx from the lungs [54, 61, 120]. These diverse EC settings require discrete EC functions to effect exchange within large capillary beds of the kidney, liver, and lung [27, 54].

The EC lining is responsible for controlling vessel damage through a complex mechanism of negative regulation, rapid response and proliferation [22, 24, 40, 53, 120, 121]. Unless activated, the endothelium normally prevents immune cells and platelets from adhering to its surface [22, 122]. Endothelial quiescence is maintained by several mediators, while vascular injury activates clotting factors, platelets, and ECs resulting in the recruitment of platelets to the endothelium [22]. ECs also have angiogenic roles migrating and proliferating to fill in endothelial cell gaps or to rebuild damaged vessels [29, 123]. EC migration and vessel remodeling requires changes in cell adherence within the endothelium, and carefully orchestrated receptor signaling responses are required to accomplish this without causing edema.

The endothelial fluid barrier is primarily derived from unique adherens junctions (AJs) composed of an EC-specific vascular-endothelial cadherin (VE-cadherin) [25, 30, 45, 96, 117, 119, 124]. EC barrier functions are increased by the presence of cell surface VE-cadherin and reduced by the dissociation and internalization of VE-cadherin [25, 30, 117]. Phosphorylated VE-cadherin is internalized by its interaction with intracellular actin complexes and this process is regulated by a variety of cellular receptors and intracellular signaling pathways [25, 124, 125]. VE-cadherin phosphorylation is downregulated by an EC-specific phosphatase (VE-phosphatase) [124, 125] and several pathways that either directly or indirectly induce AJ assembly and EC integrity by returning VE-cadherin to an unphosphorylated resting state [25, 117, 125]. Chemokines, cytokines, and growth factors indirectly act on EC adherens junctions to increase vascular permeability and thus have the potential to contribute to pathogenic vascular leakage [27, 29, 96].

4. Unique Receptors Regulate EC Permeability

The endothelium contains many unique receptors that regulate AJ assembly and positively or negatively impact AJ stability and vascular integrity [33, 96, 126–129]. Vascular endothelial growth factor (VEGF) binds to EC-specific VEGFR2 receptors and activates a Src-Rac-Pak-VE-cadherin pathway resulting in AJ disassembly and vascular permeability [25, 30, 117]. Specialized ECs contain unique VEGFR1/2/3 that respond to novel forms of VEGF (VEGF A-E) and control AJ disassembly [61, 96, 130]. LECs uniquely express VEGFR3 on their surfaces and respond to VEGF-C/D but also coexpress VEGF-A responsive VEGFR2 receptors and are further regulated by the formation of VEGFR 2/3 heterodimers [39, 42, 53, 131].

VEGF was originally discovered as a potent vascular permeability factor that induces acute edema [29, 132]. VEGF reportedly acts within 0.5 mm of its release [133], and circulating soluble VEGFRs prevent VEGF from systemically permeabilizing vessels [39, 132]. VEGF is induced by hypoxia, and reduced oxygen levels at high altitudes cause high-altitude-induced pulmonary edema (HAPE) [35, 40, 113]. This results from activating the hypoxia-induced transcription factor-1α (HIF-1α), which senses oxygen levels and transcriptionally induces VEGF [59, 128, 134, 135]. VEGF further upregulates HIF-1α, forming an autocrine loop, which amplifies hypoxia-mediated VEGF responses and causes HAPE [59, 113, 136, 137]. Although this response fosters increased gas exchange, in continued low-oxygen environments these cellular responses, instead cause pulmonary edema and in HAPE, respiratory distress [40, 110, 113, 128].

As part of the normal process of vascular repair and angiogenesis, ECs migrate in response to VEGF-A stimulation in the presence of extracellular matrix [41, 95, 138]. Permeabilizing VEGFR2 responses are normally controlled by specific cell surface integrins that modulate VEGFR2 complex formation, signaling and permeability responses [96, 97, 116, 139, 140]. Ectodomains of αβ3 and VEGFR2 form complexes that direct EC migration, a process that requires AJ disassembly, yet need to limit VEGF-A-induced permeability [96, 139]. Knocking out β3 integrins or antagonizing αβ3 results in enhanced VEGF-A directed permeability of capillaries in vivo and in vitro [97, 141, 142]. αβ3 antagonists are reported to promote the rapid recycling of internalized VEGFR2 to the cell surface, amplifying EC responses to VEGF [96, 97, 143].

β3 integrin functions are further regulated by interactions with cell surface syndecan-1 and additional interactions of
neuropilin-1 (Nrp-1) with VEGFR2 [127, 142, 144–147]. Nrp-1 is a VEGF-A coreceptor that forms an ectodomain complex with VEGFR2 that regulates the permeabilizing effects of VEGF [127, 142, 144, 145], and Nrp-1 binding to VEGFR2 is further regulated by the binding of semaphorin3A (semA3A) [145–147]. Endothelial roundabout receptors, Robo1 and Robo4, also impact VEGFR2-directed permeability through discrete signaling pathways [36, 48, 148–150]. Slit-2 binding to Robo1 and Robo4, respectively, have positive or negative effects on VEGF-A directed EC permeability [151, 152]. However, Robo 1/4 are differentially expressed in discrete EC beds suggesting the localized permeability effects of slit-2 [148, 152]. These findings indicate that many EC responses control capillary leakage through interconnected mechanisms and suggest that altering any number of orchestrated EC barrier functions can result in edema.

5. Hantavirus-Endothelial Cell Interactions

5.1. Hantavirus Binding to Inactive $\alpha_v\beta_3$ Integrins Regulates EC Functions and Permeability. Pathogenic hantaviruses bind to inactive, basal conformations of $\alpha_v\beta_3$ integrin receptors on ECs, while nonpathogenic hantaviruses interact with discrete integrins [76, 77, 79]. Receptor binding directs viral entry, but at late times postinfection cell-associated hantaviruses also negatively impact $\alpha_v\beta_3$ integrin functions [15–18, 20, 62]. Days after infection, cell-associated pathogenic hantavirus block $\alpha_v\beta_3$ integrin directed EC migration and direct the binding of quiescent platelets to the EC surface [15, 62]. Similar to antagonizing or knocking out $\alpha_v\beta_3$ integrins [96, 97], pathogenic hantavirus infection of human ECs sensitizes monolayers to the permeabilizing effects of VEGF [16, 17]. SNV-, ANDV-, and HTNV-infected ECs, but not nonpathogenic PHV or TULV infected ECs, are hyperresponsive to the permeabilizing effects of VEGF [16, 17], and VEGFR2 is hyperphosphorylated following pathogenic hantavirus infection [15, 17, 18]. Additionally, enhanced permeability of infected ECs only occurs days after infection when cell-associated hantaviruses coat the cell surface and inactivate $\alpha_v\beta_3$ integrins [15–17, 20, 73]. These findings, in the context of hypoxic HPS patients, suggest that hantavirus binding to inactive $\alpha_v\beta_3$ integrins contributes to capillary permeability in HPS. These results further suggest a mechanism for hantavirus-enhanced EC permeability that stems from disrupting normal $\alpha_v\beta_3$-VEGFR2 interactions and enhanced VEGFR2-Src-VE-cadherin signaling responses that dissociate VE-cadherin from AJs [15–17, 20, 25, 96].

One paper suggests that ANDV-infected ECs transiently induce VEGF secretion, VE-cadherin degradation, and increased EC monolayer permeability [21]. However, several studies indicate that monolayers of hantavirus-infected ECs are not permeabilized by infection alone [16, 17, 82] and instead indicate that pathogenic hantavirus infected ECs are hyperpermeabilized by VEGF [16]. Collectively, these findings demonstrate that cell surface hantaviruses alter normal EC functions that control VEGF-directed vascular permeability [15–18, 62, 153].

5.2. Potential Role of LECs in Hantavirus Edema. Pulmonary lymphatic vessels are responsible for clearing fluid from alveoli and providing a semidry state that permits gas exchange [52, 54]. Failure of lymphatic vessels to clear fluids results in lymphedema and suggests an additional mechanism for hantavirus-infected LECs to contribute to acute pulmonary edema during HPS [42, 53, 54, 154]. Analysis of pathology samples from HPS patients indicates that hantavirus antigen is present in LECs of patient lymph nodes [8, 9, 80]. Although less is known about LECs, as described above, LECs express unique cell surface receptors and their integrity is regulated by both VEGF-A and VEGF-C [42, 53, 54, 61]. Interestingly, LEC VEGFR3 receptors respond to VEGF-C and are associated with reduced tissue edema [42, 61], while inhibiting VEGFR3 signaling results in lymphedema [42, 131]. Although a recent publication indicates that ANDV infects LECs and alters LEC barrier functions [155], the role of lymphatic vessels and LEC responses remains to be investigated in HPS patients.

5.3. Hantavirus-Endothelial Edemagenic Mechanisms. Prominent pulmonary and renal dysfunction are components of both HPS and HFRS diseases and likely stem from hantavirus infection of ECs, which line vast alveolar and renal capillary beds [4–6, 8, 9, 156, 157]. HPS patients are often young adults that arrive at hospitals in acute respiratory distress [4]. Acute pulmonary edema is a hallmark of HPS, with bilateral fluid infiltrates accumulating at up to a liter per hour resulting in pulmonary insufficiency and patient hypoxia during a critical phase of the disease [4, 6, 8, 9]. The cause of acute edema following hantavirus infection is likely to be multifactorial [6, 15–18, 64, 153, 155, 158] but revolves around the ability of the hantaviruses to infect ECs within alveolar capillary beds that normally regulate edema and gas exchange within the lung.

Clues to the mechanism of hantavirus-induced edema come from disparate findings on the role of hypoxia in acute pulmonary edema and the role of $\alpha_v\beta_3$ and VEGFR2 EC responses, which are uniquely altered by pathogenic hantaviruses [6, 15, 16, 20, 155]. Hypoxia is a prominent component of HPS patients and directs VEGF secretion from endothelial, epithelial, and immune cells [5, 6, 8, 9]. Consistent with the enhanced permeability of hantavirus-infected ECs in response to VEGF [16], HPS may be the result of hypoxia-induced VEGF that leads to acute pulmonary edema and may be exacerbated by reduced lymphatic vessel fluid clearance [155]. In fact, HPS patient VEGF levels were markedly elevated in pulmonary edema fluid and PBMCs in acute early phases of HPS [159]. Although a demonstrated role for hypoxia in hantavirus-induced permeability has yet to be conclusively defined, the ability of extracorporeal membrane oxygenation (ECMO) to reduce HPS patient mortality [4, 6] strongly suggests a role for hypoxia and VEGF in the acute pulmonary edema of HPS patients.

6. Animal HPS Model

Only ANDV infection of Syrian hamsters (Mesocricetus auratus) serves as a model of hantavirus pathogenesis that mimics
human HPS in onset symptoms and lethal acute respiratory disease [19, 160, 161]. Inoculation of Syrian hamsters with ANDV, but not SNV or other HPS causing hantaviruses, induces pathology approximating human disease. ANDV causes a fatal infection of Syrian hamsters with an LD_{50} of 8 plaque-forming units. The disease is characterized by large pleural effusions, congested lungs, and interstitial pneumonitis in the absence of disrupted endothelium [19, 160, 161]. The onset of pulmonary edema coincides with a rapid increase in viremia on day 6, and large inclusion bodies and vacuoles in ultrastructural studies of infected pulmonary ECs [160, 161]. Viral antigen was localized to capillary ECs, alveolar macrophages, and splenic follicular marginal zones populated by dendritic cells. Interestingly, depletion of CD4 and CD8 T-cells had no effect on the onset, course, symptoms, or outcome of ANDV infection and indicates the absence of T-cell responses [19]. Consistent with the potential involvement of β3 integrins and VEGF in this process, ANDV binds to conserved residues within PSI domains of both human and hamster β3 integrins [20, 79]. Thus the mechanism of pathogenesis caused by ANDV is consistent with hypoxia-VEGF- directed acute pulmonary edema that occurs in the absence of T-cell-mediated pathology [19]. These findings differ from a report associating T-cell responses with HPS disease, although the same data support a lack of T-cell involvement, since half of HPS patients had no elevated T-cell responses regardless of disease severity [64]. Observed T-cell responses may instead correlate with viral clearance [63, 162]. The mechanism of pathogenesis may be further elucidated by studies in Syrian hamsters and thus provides a model of ANDV pathogenesis that permits the evaluation of therapeutics that target barrier functions of the endothelium.

7. Targeted Therapeutic Approaches for Stabilizing the Endothelium

Currently, there are no effective therapeutics for hantavirus infections or disease. Antiviral effects of interferon or the nucleoside analog ribavirin are only effective prophylactically or at very early times postinfection [14, 163]. They appear to target early viral replication but neither is effective 1-2 weeks postinfection after the onset of HPS symptoms [4-6, 163]. An alternative approach against viruses with a long disease onset may be to therapeutically target the acute pathologic response instead of viral replication. Since hantaviruses infect and alter fluid barrier functions of the endothelium, targeting EC responses that transiently stabilize the vasculature has the potential to reduce the severity and mortality of HPS [50, 129, 164]. This approach also has the advantage of being implemented at the onset of symptoms where antiviral approaches appear to be ineffective [163].

Intracellular signaling pathways coordinately regulate the adherence of ECs to the extracellular matrix, anchor receptors to cytoskeletal elements, and induce growth factor directed migration, proliferation and permeability responses [18, 35, 41, 43, 50, 96, 116, 165, 166]. The complexity of VEGF-induced permeability is further demonstrated by the reported ability of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling responses, to block VEGF-induced microvascular permeability [167–171]. This multifactorial coordination indicates why so many factors are capable of permeabilizing or stabilizing the endothelium and rationalizes their potential roles in pathogen-induced capillary leakage.

Antibody to VEGFR2 reportedly suppresses VEGF-induced pulmonary edema and suggests the potential of therapeutically antagonizing VEGFR2-Src-VE-cadherin signaling pathways as a means of reducing acute pulmonary edema during HPS [18, 25, 39, 50, 172–176]. Several well-studied VEGFR2 and Src inhibitors are in human clinical trials or are used therapeutically to treat human cancers and have the potential to reduce the severity of viral permeability-based diseases [18, 42, 50, 173, 174, 177–179]. In vitro, angiopeiotin-1 (Ang-1), sphingosine-1-phosphate (SIP), pazopanib, and dasatinib inhibited EC permeability directed by pathogenic hantaviruses [16, 18]. Ang-1 is an EC-specific growth factor that transdominantly blocks VEGFR2-directed permeability in vitro and in vivo by binding to Tie-2 receptors [180–183]. SIP is a platelet derived lipid mediator, which enhances vascular barrier functions by binding to Edg-1 receptors on the endothelium [47, 172, 173, 179, 184], while pazopanib and dasatinib are drugs that inhibit VEGFR2-Src signaling [174, 185]. Pazopanib, dasatinib, and the SIP analog FTY720 are already in clinical trials or used clinically for other purposes [34, 186]. Targeting EC responses provides a potential means of stabilizing HPS patient vessels and reducing edema. The use of SIP receptor agonists has also been shown to regulate the pathogenesis of influenza virus infection by acting on ECs and reducing immune cell recruitment and entry into the lung [172]. These findings suggest the targeting of EC functions as a means of increasing capillary barrier functions and regulating immune responses that contribute to viral pathogenesis.

The regulation of additional EC receptors that stabilize interendothelial cell AJs and fluid barrier functions of the endothelium may be considered as therapeutic targets. The Robo4 receptor has been shown to inhibit VEGFR2 responses, stabilize vessels and block vascular permeability [48, 148, 152]. This new potential target is highly expressed by lung microvascular ECs and is currently being evaluated as a therapeutic for a variety of vascular disorders [149, 152]. However, Robo4 directed stability of interendothelial cell junctions may also be applicable to reducing HPS severity.

Several additional EC receptors that bind to VEGFR2 ectodomains positively or negatively regulate αβ3-VEGFR2 functions and may provide additional therapeutic targets for regulating vascular permeability. Potential responses which need to be investigated as therapeutic targets include: NR1P1, Syndecan1 (sd1), and the insulin-like growth factor1 receptor (IGF1R), which are recruited to αβ3 ectodomain complexes [49, 141, 142, 144, 175, 187, 188]: Surfen, a heparan sulfate containing protein that reportedly blocks EC permeability [189], and Fibulin-5, a matrix protein that reportedly promotes EC adherence by binding αβ3, and is associated with emphysema [190–192]. However, inhibiting β3 receptors that are present on both platelets and ECs may
exacerbate permeability and thus the choice of therapeutic targets is likely to be critical to increasing fluid barrier functions of the endothelium. Targeting the VEGFR2 axis that regulates EC permeability may be a central mechanism for stabilizing the endothelium and reducing the severity of HPS [127, 145, 175, 193].

These findings suggest a plethora of targets that may regulate virally induced vascular permeability and which are already clinically approved for other indications. Moreover, targeting these responses may be broadly applicable to reducing the severity of HFRS and a wide range of viral infections that impact the endothelium and cause edematous diseases.

8. Future Directions and Conclusions

The endothelium plays a fundamental role in vascular disease, and stabilizing the vasculature needs to be evaluated as a means for reducing the severity and mortality of viral vascular diseases. This is especially important for viral infections that cause disease 1-2 weeks after infection, at time points when antiviral approaches are no longer viable. The ability of hantaviruses to infect LECs and alter normal fluid clearance from tissues needs to be investigated and provides a unique target and mechanism for reducing edema that has yet to be considered in HPS disease. The ability of the endothelium to regulate platelet functions, complement activation, and immune responses should also be considered as central targets for reducing the severity of viral hemorrhagic and edematous diseases.

References

[1] M. Kanerva, J. Mustonen, and A. Vaheri, “Pathogenesis of puumala and other hantavirus infections,” Reviews in Medical Virology, vol. 8, no. 2, pp. 67–86, 1998.
[2] P. Heyman, A. Vaheri, A. Lundkvist, and T. Avsic-Zupanc, “Hantavirus infections in Europe: from virus carriers to a major public-health problem,” Expert Review of Anti-Infective Therapy, vol. 7, no. 2, pp. 205–217, 2009.
[3] H. W. Lee, R. W. Lee, and K. M. Johnson, “Isolation of the etiologic agent of Korean hemorrhagic fever,” Journal of Infectious Diseases, vol. 137, no. 3, pp. 298–308, 1978.
[4] B. Chang, M. Crowley, M. Campen, and F. Koster, “Hantavirus cardiopulmonary syndrome,” Seminars in Respiratory and Critical Care Medicine, vol. 28, no. 2, pp. 193–200, 2007.
[5] J. S. Duchin, F. T. Koster, C. J. Peters et al., “Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease,” The New England Journal of Medicine, vol. 330, no. 14, pp. 949–955, 1994.
[6] F. Koster and E. Mackow, “Pathogenesis of the hantavirus pulmonary syndrome,” Future Virology, vol. 7, no. 1, pp. 41–51, 2012.
[7] S. T. Nichol, C. F. Spiropoulou, S. Morzunov et al., “Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness,” Science, vol. 262, no. 5135, pp. 914–917, 1993.
[8] K. B. Nolte, R. M. Feddersen, K. Foucar et al., “Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent,” Human Pathology, vol. 26, no. 1, pp. 110–120, 1995.
[9] S. R. Zaki, P. W. Greer, L. M. Coffield et al., “Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease,” American Journal of Pathology, vol. 146, no. 3, pp. 552–579, 1995.
[10] J. Lähdevirta, E. Enger, O. H. Hunderi, T. Traavik, and H. W. Lee, “Hantaan virus is related to hemorrhagic fever with renal syndrome in Norway,” The Lancet, vol. 2, no. 8298, p. 606, 1982.
[11] H. W. Lee, “Hemorrhagic fever with renal syndrome (HFRS). History, Hantaan virus and epidemiological features,” Scandinavian Journal of Infectious Diseases, vol. 14, no. 36, pp. 82–85, 1982.
[12] R. Yanagihiara and D. J. Silverman, “Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses,” Archives of Virology, vol. 111, no. 3-4, pp. 281–286, 1990.
[13] B. Hjelle and F. Torres-Pérez, “Hantaviruses in the Americas and their role as emerging pathogens,” Viruses, vol. 2, no. 12, pp. 2559–2586, 2010.
[14] C. Schmaljohn, “Bunyaviridae and their replication,” in Fields Virology, D. M. Knipe and P. M. Howley, Eds., vol. 1, pp. 1581–1602, Lippincott-Raven, Philadelphia, Pa, USA, 2001.
[15] I. N. Gavrilovskaya, E. E. Gorbunova, and E. R. Mackow, “Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells,” Journal of Virology, vol. 84, no. 9, pp. 4832–4839, 2010.
[16] I. N. Gavrilovskaya, E. E. Gorbunova, N. A. Mackow, and E. R. Mackow, “Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphinogine 1-phosphate inhibit hantavirus-directed permeability,” Journal of Virology, vol. 82, no. 12, pp. 5797–5806, 2008.
[17] E. Gorbunova, I. N. Gavrilovskaya, and E. R. Mackow, “Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cell,” Journal of Virology, vol. 84, no. 14, pp. 7405–7411, 2010.
[18] E. E. Gorbunova, I. N. Gavrilovskaya, T. Pepini, and E. R. Mackow, “VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability,” Journal of Virology, vol. 85, no. 5, pp. 2296–2303, 2011.
[19] C. D. Hammerbeck and J. W. Hooper, “T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome,” Journal of Virology, vol. 85, no. 19, pp. 9929–9944, 2011.
[20] T. Raymond, E. Gorbunova, I. N. Gavrilovskaya, and E. R. Mackow, “Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cell,” Journal of Virology, vol. 84, no. 14, pp. 7405–7411, 2010.
[21] P. Shrivastava-Ranjan, P. E. Rollin, and C. F. Spiropoulou, “Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin,” Journal of Virology, vol. 84, no. 21, pp. 11227–11234, 2010.
[22] W. C. Aird, “Endothelium as an organ system,” Critical Care Medicine, vol. 32, no. 5, pp. S271–279, 2004.
[23] S. M. Baumgartner-Parzer and W. K. Waldhäusl, “The endothelium as a metabolic and endocrine organ: its relation with insulin resistance,” Experimental and Clinical Endocrinology and Diabetes, vol. 109, no. 2, pp. S166–S179, 2001.
C. B. Jonsson, L. T. M. Figueiredo, and O. Vapalahti, “A high-altitude pulmonary edema,” The New England Journal of Medicine, vol. 346, no. 21, pp. 1606–1607, 2002.

J. W. Breslin, N. Gaudreault, K. D. Watson, R. Reynoso, S. Y. Yuan, and M. H. Wu, “Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism,” American Journal of Physiology, vol. 295, no. 1, pp. H709–H718, 2007.

I. N. Gavrilovskaya, T. Peresleni, E. Geimonen, and E. R. Mackow, “Pathogenic hantaviruses selectively inhibit β3 integrin directed endothelial cell migration,” Archives of Virology, vol. 147, no. 10, pp. 1913–1931, 2002.

T. Lindgren, C. Ahlm, N. Mohamed, M. Evander, H.-G. Ljunggren, and N. K. Björkström, “Longitudinal analysis of the human T cell response during acute hantavirus infection,” Journal of Virology, vol. 85, no. 19, pp. 10252–10260, 2011.

E. D. Kilpatrick, M. Terajima, F. T. Koster, M. D. Catalina, J. Cruz, and F. A. Ennis, “Role of specific CD8 T cells in the severity of a fulminating zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome,” Journal of Immunology, vol. 172, no. 5, pp. 3297–3304, 2004.

A. J. Battisti, Y. K. Chu, P. R. Chipman, B. Kaufmann, C. N. F. Voelkel, “High-altitude pulmonary edema, ” J. W. Breslin, N. Gaudreault, K. D. Watson, R. Reynoso, S. Y. Yuan, and M. H. Wu, “Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism,” American Journal of Physiology, vol. 295, no. 1, pp. H709–H718, 2007.

I. N. Gavrilovskaya, T. Peresleni, E. Geimonen, and E. R. Mackow, “Pathogenic hantaviruses selectively inhibit β3 integrin directed endothelial cell migration,” Archives of Virology, vol. 147, no. 10, pp. 1913–1931, 2002.

T. Lindgren, C. Ahlm, N. Mohamed, M. Evander, H.-G. Ljunggren, and N. K. Björkström, “Longitudinal analysis of the human T cell response during acute hantavirus infection,” Journal of Virology, vol. 85, no. 19, pp. 10252–10260, 2011.

E. D. Kilpatrick, M. Terajima, F. T. Koster, M. D. Catalina, J. Cruz, and F. A. Ennis, “Role of specific CD8 T cells in the severity of a fulminating zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome,” Journal of Immunology, vol. 172, no. 5, pp. 3297–3304, 2004.

A. J. Battisti, Y. K. Chu, P. R. Chipman, B. Kaufmann, C. N. F. Voelkel, “High-altitude pulmonary edema, ” J. W. Breslin, N. Gaudreault, K. D. Watson, R. Reynoso, S. Y. Yuan, and M. H. Wu, “Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism,” American Journal of Physiology, vol. 295, no. 1, pp. H709–H718, 2007.

I. N. Gavrilovskaya, T. Peresleni, E. Geimonen, and E. R. Mackow, “Pathogenic hantaviruses selectively inhibit β3 integrin directed endothelial cell migration,” Archives of Virology, vol. 147, no. 10, pp. 1913–1931, 2002.

T. Lindgren, C. Ahlm, N. Mohamed, M. Evander, H.-G. Ljunggren, and N. K. Björkström, “Longitudinal analysis of the human T cell response during acute hantavirus infection,” Journal of Virology, vol. 85, no. 19, pp. 10252–10260, 2011.

E. D. Kilpatrick, M. Terajima, F. T. Koster, M. D. Catalina, J. Cruz, and F. A. Ennis, “Role of specific CD8 T cells in the severity of a fulminating zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome,” Journal of Immunology, vol. 172, no. 5, pp. 3297–3304, 2004.

A. J. Battisti, Y. K. Chu, P. R. Chipman, B. Kaufmann, C. N. F. Voelkel, “High-altitude pulmonary edema, ” J. W. Breslin, N. Gaudreault, K. D. Watson, R. Reynoso, S. Y. Yuan, and M. H. Wu, “Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism,” American Journal of Physiology, vol. 295, no. 1, pp. H709–H718, 2007.
[154] P. Saharinen and T. V. Petrova, "Molecular regulation of lymphangiogenesis," *Annals of the New York Academy of Sciences*, vol. 1014, pp. 76–87, 2004.

[155] I. N. Gavrilovskaya, E. E. Gorbunova, and E. R. Mackow, "ANDV infection offlymphoendothelial cells causes giant cell and enhanced permeability responses that are rapamycin and VEGF-C-sensitive," *Journal of Virology*. In press.

[156] J. Lädevirta, "Clinical features of HFRS in Scandinavia as compared with East Asia," *Scandinavian Journal of Infectious Diseases*, vol. 36, pp. 93–95, 1982.

[157] A. S. Khan, R. F. Khubaz, L. R. Armstrong et al., "Hantavirus pulmonary syndrome: the first 100 US cases," *Journal of Infectious Diseases*, vol. 173, no. 6, pp. 1297–1303, 1996.

[158] T. Krakauer, J. W. Leduc, and H. Krakauer, "Serum levels of tumor necrosis factor-α, interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome," *Viral Immunology*, vol. 8, no. 2, pp. 75–79, 1995.

[159] I. N. Gavrilovskaya, E. E. Gorbunova, F. Koster, and E. R. Mackow, "Elevated VEGF levels in pulmonary edema fluid and pbscs from patients with acute hantavirus pulmonary syndrome," In press.

[160] J. W. Hooper, T. Larsen, D. M. Custer, and C. S. Schmaljohn, "A lethal disease model for hantavirus pulmonary syndrome," *Virology*, vol. 289, no. 1, pp. 6–14, 2001.

[161] V. Wahl-Jensen, J. Chapman, L. Asher et al., "Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters," *Journal of Virology*, vol. 81, no. 4, pp. 7449–7462, 2007.

[162] D. Safronetz, M. Zivcec, R. LaCasse et al., "Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus," *PLoS Pathogens*, vol. 7, no. 12, Article ID e1002426, 2011.

[163] C. B. Jonsson, J. Hooper, and G. Mertz, "Treatment of hantavirus pulmonary syndrome," *Antiviral Research*, vol. 78, no. 1, pp. 162–169, 2008.

[164] C. A. Jones, N. R. London, H. Chen et al., "Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability," *Nature Medicine*, vol. 14, no. 4, pp. 448–453, 2008.

[165] Y. Walle, F. Cand, F. Cruzalegui et al., "Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site," *Oncogene*, vol. 26, no. 7, pp. 1067–1077, 2007.

[166] Y. Wang, G. Jin, H. Miao, J. Y. S. Li, S. Usami, and S. Chien, "Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 6, pp. 1774–1779, 2006.

[167] S. Huber, C. J. Bruns, G. Schmid et al., "Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis," *Kidney International*, vol. 71, no. 8, pp. 771–777, 2007.

[168] D. D. Kim, D. M. Kleinman, T. Kanetaka et al., "Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo," *Microcirculation*, vol. 17, no. 2, pp. 128–136, 2010.

[169] S. C. Land and A. R. Tee, "Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif," *Journal of Biological Chemistry*, vol. 282, no. 28, pp. 20534–20543, 2007.

[170] T. L. Phung, K. Ziv, D. Dabydeen et al., "Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin," *Cancer Cell*, vol. 10, no. 2, pp. 159–170, 2006.

[171] Q. Xue, J. A. Nagy, E. J. Manseau, T. L. Phung, H. F. Dvorak, and L. E. Benjamin, "Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164-Driven Angiogenesis, in Part by Blocking S6Kinase," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 29, no. 8, pp. 1172–1178, 2009.

[172] J. R. Teijaro, K. B. Walsh, S. Cahalan et al., "Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection," *Cell*, vol. 146, no. 6, pp. 980–991, 2011.

[173] G. Schmid, M. Guba, I. Ischenko et al., "The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1," *Journal of Cellular Biochemistry*, vol. 101, no. 1, pp. 259–270, 2007.

[174] K. Porkka, H. J. Houry, R. L. Paquette, Y. Matloub, R. Sinha, and J. E. Cortes, "Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion," *Cancer*, vol. 116, no. 2, pp. 377–386, 2010.

[175] L. M. Acevedo, S. Barillas, S. M. Weis, J. R. Göthert, and D. A. Cheresh, "Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor," *Blood*, vol. 111, no. 5, pp. 2674–2680, 2008.

[176] D. Xu, M. M. Fuster, R. Lawrence, and J. D. Esko, "Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability," *Journal of Biological Chemistry*, vol. 286, no. 1, pp. 737–745, 2011.

[177] V. Brinkmann, "Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology," *Pharmacology and Therapeutics*, vol. 115, no. 1, pp. 84–105, 2007.

[178] X. Peng, P. M. Hassoun, S. Sammani et al., "Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury," *American Journal of Respiratory and Critical Care Medicine*, vol. 169, no. 11, pp. 1245–1251, 2004.

[179] T. Sanchez, T. Estrada-Hernandez, J. H. Paik et al., "Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability," *Journal of Biological Chemistry*, vol. 278, no. 47, pp. 47281–47290, 2003.

[180] R. K. Jain and L. L. Munn, "Leaky vessels? Call ang1!," *Nature Medicine*, vol. 6, no. 2, pp. 131–132, 2000.

[181] L. Pizurki, Z. Zhou, K. Glynos, C. Roussos, and A. Papaetropoulos, "Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production," *British Journal of Pharmacology*, vol. 139, no. 2, pp. 329–336, 2003.

[182] S. C. Satchell, K. L. Anderson, and P. W. Mathieson, "Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties," *Journal of the American Society of Nephrology*, vol. 15, no. 3, pp. 566–574, 2004.

[183] G. Thurston, C. S. Tegeder, T. Loder, S. S. Mehta, and N. F. N. Garcia, "In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights," *Cellular Signalling*, vol. 17, no. 2, pp. 131–139, 2005.

[184] K. Podar, G. Tonon, M. Sattler et al., "The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma,"
Advances in Virology

Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 51, pp. 19478–19483, 2006.

[186] B. J. McVerry, X. Peng, P. M. Hassoun, S. Sammani, B. A. Simon, and J. G. N. Garcia, “Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 9, pp. 987–993, 2004.

[187] M. R. Morgan, M. J. Humphries, and M. D. Bass, “Synergistic control of cell adhesion by integrins and syndecans,” Nature Reviews Molecular Cell Biology, vol. 8, no. 12, pp. 957–969, 2007.

[188] D. M. Beauvais and A. C. Rapraeger, “Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation,” Journal of Cell Science, vol. 123, no. 21, pp. 3796–3807, 2010.

[189] M. Schuksz, M. M. Fuster, J. R. Brown et al., “Surfen, a small molecule antagonist of heparan sulfate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13075–13080, 2008.

[190] A. R. Albig and W. P. Schiemann, “Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells,” DNA and Cell Biology, vol. 23, no. 6, pp. 367–379, 2004.

[191] L. J. Freeman, A. Lomas, N. Hodson et al., “Accelerated publication fibulin-5 interacts with fibrillin-1 molecules and microfibrils,” Biochemical Journal, vol. 388, no. 1, pp. 1–5, 2005.

[192] A. Guadall, M. Orriols, R. Rodriguez-Calvo et al., “Fibulin-5 is up-regulated by hypoxia in endothelial cells through a hypoxia-inducible factor-1 (HIF-1α)-dependent mechanism,” Journal of Biological Chemistry, vol. 286, no. 9, pp. 7093–7103, 2011.

[193] Z. K. Otrock, J. A. Makarem, and A. I. Shamseddine, “Vascular endothelial growth factor family of ligands and receptors: review,” Blood Cells, Molecules, and Diseases, vol. 38, no. 3, pp. 258–268, 2007.